Certain members of the thiazolidinedione (TZD) family of the peroxisome proliferator-activated receptor g (PPARg) agonists, such as troglitazone and ciglitazone, exhibit antitumor activities; however, the underlying mechanism remains inconclusive. Substantial evidence suggests that the antiproliferative effect of these TZD members in cancer cells is independent of PPARg activation. To discern the role of PPARg in the antitumor effects of TZDs, we have synthesized PPARginactive TZD analogs which, although devoid of PPARg activity, retain the ability to induce apoptosis with a potency equal to that of their parental TZDs in cancer cell lines with varying PPARg expression status. Mechanistic studies from this and other laboratories have further suggested that troglitazone and ciglitazone mediate antiproliferative effects through a complexity of PPARg-independent mechanisms. Evidence indicates that troglitazone and ciglitazone block BH3 domain-mediated interactions between the anti apoptotic Bcl-2 (B-cell leukemia/lymphoma 2) members Bcl-2/Bcl-xL and proapoptotic Bcl-2 members. Moreover, these TZDs facilitate the degradation of cyclin D1 and caspase-8-related FADD-like IL-l-converting enzyme (FLICE)-inhibitory protein through proteasome-mediated proteolysis, and down-regulate the gene expression of prostate-specific antigen gene expression by inhibiting androgen activation of the androgen response elements in the promoter region. More importantly, dissociation of the effects of TZDs on apoptosis from their original pharmacological activity (i.e. PPARg activation) provides a molecular basis for the exploitation of these compounds to develop different types of molecularly targeted anticancer agents. These TZD-derived novel therapeutic agents, alone or in combination with other anticancer drugs, have translational relevance in fostering effective strategies for cancer treatment.
Introduction
Thiazolidinediones (TZDs), including troglitazone (Rezulin), rosiglitazone (Avandia), pioglitazone (Actos), and ciglitazone, are synthetic ligands for the peroxisome proliferator-activated receptor g (PPARg) (for review see Day 1999) (Fig. 1 ). This family of PPARg agonists improves insulin sensitivity by increasing transcription of certain insulin-sensitive genes involved in the metabolism and transport of lipids in adipocytes, such as lipoprotein lipase, adipocyte fatty acid-binding protein, acyl-CoA synthase, and fatty acid transport protein (Koeffler 2003) . In addition, TZDs have been demonstrated to promote the differentiation of preadipocytes by mimicking certain genomic effects of insulin on adipocytes (Tontonoz et al. 1994) , and to regulate glucose homeostasis (Saltiel & Olefsky 1996) . Consequently, the TZDs offer a new type of oral therapy in type II diabetes to reduce insulin resistance and to assist glycemic control.
Recent evidence indicates that certain TZD members, especially troglitazone and ciglitazone, exhibit moderate antiproliferative activities against many epithelial-derived human cancer cell lines including those of prostate (Kubota et al. 1998) , breast (Yin et al. 2001) , colon (Kato et al. 2004) , thyroid (Ohta et al. 2001) , lung (Tsubouchi et al. 2000) , and pituitary carcinoma (Heaney et al. 2003) . This growth inhibition was linked to the G1 phase cell cycle arrest through the up-expression of the cyclin-dependent kinase inhibitors p21 and p27 (Koga et al. 2001 , 2003 , Takeuchi et al. 2002 , Yoshizawa et al. 2002 , Bae et al. 2003 and/or repression of cyclin D1 expression (Wang et al. 2001 , Yin et al. 2001 , Lapillonne et al. 2003 , Qin et al. 2003 . Meanwhile, data from this and other laboratories have indicated that normal prostate epithelial cells (not shown) and T lymphocytes (Harris & Phipps 2002) are more resistant to apoptotic induction by these TZDs. In the light of this cancer-specific effect, the potential use of these PPARg agonists as chemopreventive agents has received much attention (for a review see Badawi & Badr 2002 , Kopelovich et al. 2002 , Smith & Kantoff 2002 , Bull 2003 , Koeffler 2003 , Leibowitz & Kantoff 2003 , Grommes et al. 2004 , Jiang et al. 2004 . Moreover, animal model studies have demonstrated the in vivo efficacy of troglitazone in colon, prostate, and liver cancers (Kubota et al. 1998 , Sarraf et al. 1998 , Yu et al. 2006 and that of rosiglitazone in pituitary tumors (Henry et al. 2000 , Heaney et al. 2002 . Despite these advances, the mechanism underlying the antitumor effects of TZD remains unclear. As PPARg-mediated effects of TZDs promote the differentiation of preadipocytes, one school of thought attributes the same mechanism to the terminal differentiation and cell cycle arrest of tumor cells (Tontonoz et al. 1997) . However, the PPARg-target genes that mediate the antiproliferative effects remain elusive, as genomic responses to PPARg activation in cancer cells are highly complicated (Gupta et al. 2001) . Reported causal mechanisms include attenuated expression of protein phosphatase 2A (Altiok et al. 1997) , cyclins D1 and E, inflammatory cytokines and transcription factors (Koeffler 2003) , and increased expression of an array of gene products linked to growth regulation and cell maturation (Gupta et al. 2001) .
On the other hand, several lines of evidence have suggested that the inhibitory effect of TZDs on tumor cell proliferation is independent of PPARg activation. For example, sensitivity of cancer cells to TZD-induced growth inhibition does not correlate with the level of PPARg expression, and there exists a three orders of magnitude discrepancy between the concentration required to produce antitumor effects and that to modify insulin action (Day 1999) . In addition, the in vitro antitumor effects appear to be structure specific irrespective of their potency in PPARg activation, i.e. troglitazone and ciglitazone are active while rosiglitazone and pioglitazone are not. To date, an array of nonPPARg targets has been implicated in the antitumor activities of troglitazone and/or ciglitazone in different cell systems, which include intracellular Ca 2þ stores (Palakurthi et al. 2001) , phosphorylating activation of extracellular signal-regulated kinases (Gouni-Berthold et al. 2001 , Takeda et al. 2001 ), c-Jun N-terminal protein kinase, and p38 (Bae & Song 2003 , up-regulation of early growth response-1 (Baek et al. 2003) , the cyclin-dependent kinase (CDK) inhibitors p27 kip1 (Motomura et al. 2000) and p21
WAF=CIP1 (Sugimura et al. 1999) , the tumor suppressor protein p53 and the p53-responsive stress protein Gadd45 (Okura et al. 2000) , and altered expression of B-cell leukemia/ lymphoma 2(Bcl-2) family members (Bae & Song 2003) . However, some of these targets appear to be cell type specific due to differences in signaling pathways regulating cell growth and survival in different cell systems.
In considering the translational potential of using PPARg ligand in cancer prevention and therapy, our research has focused on elucidating the mechanisms underlying the antitumor effect of TZDs. In the following sections, evidence that dissociates the effect of TZDs on apoptosis from PPARg-activating activity is presented. This review also provides an Figure 1 Chemical structures of troglitazone, ciglitazone, rosiglitazone, and pioglitazone, and their respective PPARg-inactive Á2 derivatives (Á2-TG, Á2-CG, Á2-RG, and Á2-PG). The introduction of the double bond adjoining the terminal thiazolidinedione ring results in the abrogation of the PPARg ligand property.
overview of recent findings from this and other laboratories concerning plausible PPARg-independent targets that underlie TZD-mediated apoptosis. Equally importantly, the use of TZDs as a molecular platform to develop novel mechanism-based therapeutic agents will be discussed.
Demonstration of PPAR-independent antiproliferative effects of TZDs
We hypothesized that if TZDs mediate antitumor effects independently of PPARg, one would be able to dissociate these two pharmacological activities via structural modifications of these molecules. This premise was corroborated by the development of a novel class of PPARg-inactive TZD analogs, which was accomplished by introducing a double bond adjoining the terminal thiazolidine-2,4-dione ring ( Fig. 1) (Shiau et al. 2005) . Two lines of evidence indicate that this structural modification abrogated the ligand-binding ability of PPARg. First, these Á2 analogs (5-[4-(6-hydroxy-2,5,
and (5-[4-(1-methyl-cycohexylmethoxy)-benzylidene]-thiazolidine-2,4-dione (Á2-CG)) were inactive in PPARg activation according to a PPARg transcription factor ELISA (Shiau et al. 2005) . Secondly, DU-145 prostate cancer cells were transfected with a reporter construct that contains PPAR response element (PPRE) upstream of a luciferase gene. None of these Á2 derivatives elicited any significant PPARg transactivation. The loss of PPARg activity was presumably attributed to the structural rigidity, as a result of the double bond introduction surrounding the heterocyclic system. These PPARg-inactive TZD derivatives were examined in two prostate cancer cell lines with distinct PPARg expression status, androgen-independent PC-3 and androgen-dependent LNCaP. Between these two cell lines, PPARg was highly expressed in PC-3 cells, but was deficient in LNCaP cells ( Fig. 2A) . Nevertheless, despite a deficiency in PPARg, LNCaP cells exhibited a higher degree of susceptibility to troglitazone-mediated in vitro antitumor effects compared with the PPARg-rich PC-3 cells (Fig. 2B, left panel) . In addition, Á2-TG, although devoid of PPARg-activating activity, was more potent than troglitazone in suppressing cell proliferation in both cell lines. This growth inhibition was attributable to apoptotic death, as evidenced by mitochondrial cytochrome c release in PC-3 cell (Fig. 2B, right panel) .
Similar results were obtained with ciglitazone and Á2-CG with respect to cytochrome c-dependent apoptotic death in PC-3 cells (Fig. 3) , with relative potency similar to that of troglitazone and Á2-TG. In contrast, rosiglitazone, pioglitazone, and their Á2 derivatives showed marginal effects, even at 50 mM, on cell death in PC-3 cells (Fig. 3) .
Together, these data suggest that TZDs mediated apoptosis induction in prostate cancer cell systems irrespective of PPARg activation. Mechanistic studies from this and other laboratories have further suggested that TZDs mediate proapoptotic effects through a complexity of PPARg-independent molecular targets, which include, but are not limited to, Bcl-2/Bcl-xL, cyclin D1, FADD-like IL-l-converting enzyme (FLICE)-inhibitory protein (FLIP), and prostate specific antigen (PSA), which are summarized as follows.
TZD-induced apoptosis involves the inhibition of Bcl-xL and Bcl-2 function
The functional relationship between antiapoptotic and proapoptotic Bcl-2 members in the regulation of mitochondrial integrity is well documented (Cory et al. 2003) . Bcl-2 and Bcl-xL mediate their antiapoptotic function through the sequestration of Bad, Bax, and other proapoptotic Bcl-2 members via BH3 domain-facilitated heterodimerization, thereby abrogating their ability to induce mitochondrial cytochrome c release (Diaz et al. 1997 , Sattler et al. 1997 , Otter et al. 1998 , Nouraini et al. 2000 , Finnegan et al. 2001 . Thus, a balance between these two types of Bcl-2 members plays a crucial role in the regulation of the apoptotic machinery.
Effect of troglitazone on the expression of Bcl-2 family members
It has been reported that troglitazone at high doses repressed Bcl-2 expression in MCF-7 breast cancer (Elstner et al. 1998), and increased the expression level of the proapoptotic proteins Bad and Bax in HepG2 hepatoma cells (Bae & Song 2003) . This phenomenon, however, appears to be cell line specific. In our study, troglitazone, even at 30 mM, did not cause appreciable changes in the expression of any of the aforementioned Bcl-2 members in PC-3 cells with the exception of a slight decrease in Bad expression at 24-h exposure (Fig. 4) (Shiau et al. 2005) . 
Inhibition of Bcl-xL and Bcl-2 function
Nevertheless, we obtained several lines of evidence that troglitazone and ciglitazone might inhibit the antiapoptotic function of Bcl-xL/Bcl-2 by blocking BH3 domain-mediated heterodimerization with proapoptotic Bcl-2 members (Shiau et al. 2005) . First, data from the competitive fluorescence polarization analysis suggest that troglitazone, ciglitazone, and their Á2 counterparts compete with a Bak BH3-domain peptide for binding to Bcl-xL and Bcl-2. Moreover, the potency of TZDs and their Á2 analogs in inhibiting this peptide binding correlated with the respective effectiveness in inducing apoptotic death in LNCaP and PC-3 prostate cancer cells (Table 1) . For example, the inability of rosiglitazone and pioglitazone to trigger apoptotic death was reflected in their lack of potency in disrupting interactions between Bcl-xL/Bcl-2 and the Bak BH3 domain. Secondly, troglitazone and Á2-TG perturbed the dynamics of intracellular Bcl-2/Bak and Bcl-xL/ Bak interactions in PC-3 cells, i.e. the level of Bak associated with Bcl-2 and Bcl-xL was greatly reduced in troglitazone-and Á2-TG-treated cells as compared with DMSO control (Fig. 5A) . As a result, liberation of proapoptotic Bcl-2 members induced apoptosis by facilitating cytochrome c release and consequent caspase-9 activation (Fig. 5B) .
Thirdly, overexpression of Bcl-xL provided LNCaP cells conferred protection against troglitazone-and Á2-TG-induced apoptosis. As shown in Fig. 5C , ascending expression levels of Bcl-xL in three transfected LNCaP stable clones (B11, B1, and B3) diminished the susceptibility to troglitazone-and Á2-TG-induced apoptosis death as compared with that of parental LNCaP cells. The extent of cytoprotection conferred by ectopic BclxL correlated with the Bcl-xL expression level. The excessive expression in B3 cells especially completely overcame the apoptotic effect of troglitazone and Á2-TG.
Antiproliferative mechanisms involve modulation of cell cycle effectors
Troglitazone and ciglitazone repress cyclin D1 expression via proteasome-facilitated proteolysis PPARg agonists, including 15-deoxy-Á12,14-prostaglandin J 2 (PGJ 2 ), troglitazone, and ciglitazone, at high doses, have been shown to down-regulate cyclin D1 expression as part of their action to cause cell-cycle arrest and growth inhibition in breast cancer cells (Wang et al. 2001 , Yin et al. 2001 , Lapillonne et al. 2003 , Qin et al. 2003 , Huang et al. 2005 . Cyclin D1 is a downstream effector of diverse proliferative and transforming signaling pathways, including those mediated by b-catenin (Shtutman et al. 1999) , estrogen receptor . In mammary cells, transcriptional activation of cyclin D1 in response to these mitogenic signals leads to G 1 /S progression and increased proliferation. Cyclin D1 overexpression has been implicated in oncogene-induced mammary tumorigenesis; it has been noted that more than 50% of primary breast carcinomas correlated with poor prognosis (McIntosh et al. 1995 , Kenny et al. 1999 . In addition to activating cyclin-dependent kinases (CDKs) and sequestering CDK inhibitors in the G 1 /S transition, the function of cyclin D1 as a CDKindependent activator of ER is especially noteworthy (Neuman et al. 1997 , Zwijsen et al. 1997 , McMahon et al. 1999 , Lamb et al. 2000 . Cyclin D1 overexpression confers resistance to antiestrogens in breast cancer cells (Musgrove et al. 2001 , Hui et al. 2002 , and represents a negative predictive factor for tamoxifen response (Stendahl et al. 2004 ). Together, these findings suggest that an anti-cyclin D1 therapy might be highly specific for treating human breast cancer (Yu et al. 2001 ). An urgent need therefore exists to develop potent cyclin D1-ablative agents that are effective in the therapeutically attainable range ( 5 mM) for breast cancer prevention and/or therapy.
As troglitazone provides an attractive starting point for this drug discovery effort, the mechanism underlying its effect on cyclin D1 repression constituted the focus of our recent investigation (Huang et al. 2005) . Several lines of evidence suggest that troglitazone mediates the repression of cyclin D1 expression via a PPARg-independent mechanism. First, Á2-TG and Á2-CG, although devoid of PPARg activity, were able to mediate cyclin D1 ablation with slightly higher potency than troglitazone and ciglitazone respectively in MCF-7 breast cancer cells (Fig. 6A) , while the more potent PPARg agonists rosiglitazone and pioglitazone lacked appreciable activity at comparable concentrations (not shown).
Secondly, troglitazone-mediated cyclin D1 downregulation could not be rescued by the PPARg antagonist 2-chloro-5-nitro-N-phenylbenzamide (GW9662). Thirdly, despite significantly higher PPARg expression, MDA-MB-231 breast cancer cells were less susceptible to troglitazone-induced cyclin D1 ablation than MCF-7 cells. Although it has been reported that the PPARg ligands PGJ 2 and troglitazone inhibited cyclin D1 transcription by activating PPARg in MCF-7 cells (Wang et al. 2001) and mouse skin keratinocytes (He et al. 2004) respectively, data from this and other laboratories have indicated that troglitazone and ciglitazone mediate cyclin D1 ablation in MCF-7 cells by facilitating ubiquitination and proteasomal (2006) 13 401-413 www.endocrinology-journals.org proteolysis in a specific manner (Qin et al. 2003 , Huang et al. 2005 . For example, PCR analysis indicates that the mRNA level of cyclin D1 remained unaltered in drug-treated cells, indicating that the repression was mediated at the post-transcriptional level. Moreover, this drug-induced cyclin D1 repression could be rescued by proteasome inhibitors, and was preceded by increased ubiquitination.
Endocrine-Related Cancer
It is noteworthy that the troglitazone-mediated cyclin D1 ablation was highly specific. Among all cyclins and CDKs examined (cyclins D2. D3, A, B, and E, and CDKs 2 and 4) as well as p53, only cyclin D2 and CDK4 showed a slight decrease in the expression level in drug-treated MCF-7 cells (Fig. 6B) .
Troglitazone up-regulates the expression of the CDK inhibitor p21 CIP1
Moreover, western blotting analysis indicates that, in MCF-7 cells, troglitazone up-regulated the expression of p21 CIP1 , while p27 KIP1 exhibited a dose-dependent decrease (Fig. 6B) 
Other molecular mechanisms
In addition to the aforementioned effects, several other PPARg-independent mechanisms have been reported to account for the antiproliferative action of TZDs in different cancer cells. Among these proposed mechanisms, the effects on proteasomemediated degradation of FLIP (Kim et al. 2002) and down-regulation of PSA expression (Kubota et al. 1998 , Hisatake et al. 2000 are especially noteworthy in light of their clinical implications in cancer therapy.
FLIP inhibits apoptosis induced by tumor necrosis factor (TNF) family death receptor by blocking caspase 8 activation (Wajant 2003) . As demonstrated by antisense-mediated down-regulation, decreased expression of FLIP confers sensitivity against death receptor-induced apoptosis. Inhibition of FLIP expression in tumor cells is of particular importance to TNF-related apoptosis inducing ligand (TRAIL)-based cancer therapy (Wajant 2003) . TRAIL is the ligand of death receptors, and has attracted substantial clinical interests in light of its ability to induce apoptosis preferentially in tumor cells. However, not all tumor cells respond to TRAIL, in part because of intracellular resistance mechanisms (Ashkenazi 2002). Recent reports indicate that PPARg agonists including troglitazone could sensitize tumor cells to TRAIL-induced apoptosis (Goke et al. 2000 , Kim et al. 2002 as a result of the proteasome-dependent proteolysis of FLIP (Kim et al. 2002) . As the mode of FLIP down-regulation is reminiscent of that of cyclin D1, there may exist cross-reactivity in troglitazonemediated proteasomal degradation of both proteins.
PSA is used as a serum biomarker for diagnosis and progression of prostate cancer (Polascik et al. 1999) . It has been shown that troglitazone at concentrations ( 10 mM) lower than that required for growth inhibition (!20 mM) was able to downregulate PSA expression in LNCaP prostate cancer cells through the inhibition of androgen activation of the androgen response elements in the regulatory region of the PSA gene (Hisatake et al. 2000) . Moreover, the same report indicates that troglitazone at 600ÿ800 mg/day stabilized PSA levels in a prostate cancer patient with a radical prostectomy throughout a 14-month period.
Pharmacological exploitation of troglitazone to develop novel mechanism-based anticancer agents
The above discussion clearly demonstrates that the antiproliferative activity of troglitazone is mediated through multiple molecular targets independently of PPARg. From a mechanistic perspective, dissociation of the aforementioned pharmacological activities from PPARg activation provide a molecular rationale to use troglitazone as a starting point to develop novel mechanism-based therapeutic agents. The proof of the principle of this premise is 5-[4-(6-allyoxy-2,5,7,8-tetramethyl-chroman-2-yl-methoxy)-benzylidene]-2,4-thizolidinedione (Á2-TG-6) (Huang et al. 2005) , a close structural analog that exhibited an order of magnitude higher potency than troglitazone and Á2-TG in repressing cyclin D1 expression and inhibiting MCF-7 cell proliferation (Fig. 7) .
As shown, Á2-TG-6 reduced cyclin D1 levels at concentrations as low as 2.5 mM compared with !20 mM for Á2-TG (Fig. 7B) , and exhibited IC 50 of 8 mM versus 55 mM for Á2-TG in inhibiting MCF-7 cell viability (Fig. 7C ). This antiproliferative effect was attributable to apoptosis induction, as evidenced by poly(ADP-ribose)polymerase (PARP) cleavage (Fig. 7D) . Lead optimization of Á2-TG-6 to generate more potent cyclin D1-ablative agents is currently undergoing, the clinical implication of which is multifold. First, cyclin D1 ablation provides specific protection against breast carcinogenesis (Yu et al. 2001) . Secondly, in light of the role of cyclin D1 overexpression in antiestrogen resistance, cyclin D1 ablation may help overcome the resistance. Thirdly, the synergistic interaction between flavopiridol and trastuzumab in inhibiting breast cancer cell proliferation is attributable, in part, to the reduction of cyclin D1 expression (Wu et al. 2002) . These agents may sensitize cells to the antiproliferative action of either CDK inhibition or Her-2/Akt inhibition.
A similar approach has been taken to develop a potent Bcl-2/Bcl-xL inhibitor (TG-88) with an IC 50 of 1.8 mM based on fluorescence polarization analysis. Oral TG-88 at a daily dose of 100 or 200 mg/kg was effective in suppressing PC-3 xenograft tumor growth without causing weight loss or apparent toxicity, indicating its oral bioavailability and potential clinical use (Shiau et al. 2005) . It is also noteworthy that the structural requirement for Bcl-2/Blc-xL inhibition differed from that of cyclin D1 ablation.
Conclusion
Data from this and other laboratories have clearly demonstrated that the effect of TZDs on triggering apoptosis in cancer cells is dissociated from that of PPARg activation. To date, a number of important signaling mechanisms have been identified to underlie TZD-mediated antitumor activities, including, but not limited to, inhibition of Bcl-2/Bcl-xL function and repression of the expression of cyclin D1, FLIP, and PSA. These findings provide molecular underpinnings for the molecular exploitation of troglitazone and ciglitazone to develop different types of molecularly targeted anticancer agents. Our data indicate that structural preference for Bcl-2/Bcl-xL inhibition differs from that of cyclin D1 ablation, while that between cyclin D1 and FLIP is currently being investigated. Because of the heterogeneity in the cancer cell population, various genetic lesions/molecular defects allow different subsets of tumor cells to exhibit differential sensitivity to apoptotic signals generated by different chemotherapeutic agents. Thus, these troglitazonederived agents in combination with other therapeutic agents have translational relevance in fostering effective strategies for cancer treatment. 
